Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure?
Dressler
D
D
Department of Neurology, University of Rostock, Germany.
Zettl
U
U
Benecke
R
R
Bigalke
H
H
D000328:Adult; D019274:Botulinum Toxins, Type A / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D009465:Neuromuscular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014103:Torticollis / Q000188:drug therapy*; D017211:Treatment Failure
D016756:Immunoglobulins, Intravenous; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A